Imagine transforming hours of tedious data work into mere minutes of productivity. That’s the promise of Microsoft Copilot in Excel, a new AI-powered assistant designed to transform how you manage, ...

Changpeng Zhao had pleaded guilty to failure to protect against money laundering. The families of victims of Hamas’ Oct 7, 2023, attack on Israel filed a lawsuit against the cryptocurrency fund ...

WASHINGTON — Families of victims of Hamas’ Oct. 7, 2023, attack on Israel sued Binance Monday, claiming that the world’s largest cryptocurrency trading platform — and its recently pardoned founder and ...

Jake Fillery is an Evergreen Editor for Game Rant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...

Imagine investing in a promising project, only to realize years later that it’s taking far longer than expected to recoup your initial outlay. Wouldn’t it have been invaluable to know upfront how long ...

Sam Altman‘s Tools for Humanity biometric verification company is hitting roadblocks on its path to global adoption, according to Business Insider. The volleyball-sized metal sphere named Orb scans ...

As vicious infighting in President Donald Trump’s Make America Great Again movement over the controversial H-1B visa magnifies uncertainty for foreign workers in the U.S., Canada last week approved a ...

WASHINGTON, DC - MARCH 18: The U.S. Department of Labor building is seen behind a sign marking the location of the agency's headquarters on March 18, 2025, in Washington, D.C. The Department of ...

LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at ...

Elon Musk’s SpaceX is on the road to getting $7.5 million in Texas tax breaks for two major expansion projects at the city of Starbase that are valued at nearly $1 billion. During a Starbase City ...

The MarketWatch News Department was not involved in the creation of this content. ZYNLONTA(R) in combination with glofitamab (COLUMVI(R)) demonstrated an 89.8% ORR and 77.6% CR across the 49 ...